Vifor Pharma (Switzerland)

Vifor Pharma (Switzerland)

CSL Vifor is a global specialty pharmaceuticals company in the treatment areas of iron deficiency, dialysis, nephrology & rare disease. It is headquartered in Switzerland and consists of CSL Vifor, Vifor Fresenius Medical Care Renal Pharma and Sanifit Therapeutics. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Vifor Pharma (Switzerland), Switzerland, covering academic research published from 2000 to 2024. Read More.


Open Access Percentage

51%


Total
Publications

1K


Total Open
Publications

515


Total
Citations

30K


Open Access
Percentage

51%


Total
Publications

1K


Total Open
Publications

515


Total
Citations

30K

Wikipedia

Website

download

Breakdown

21% 25% 4% 50%

Publisher Open

21%

Both

25%

Other Platform Open

4%

Closed

50%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

0102030405060708090100Total Publications
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

37%OA Journal

OA Journal 37%

172

Hybrid 27%

126

No Guarantees 36%

163

Other Platform Open

Domain 74%

222

Institution 38%

113

Other Internet 18%

53

Preprint 5%

16

Public 2%

7

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
222
DOI
Other Internet
43
DANS - Data Archiving and Networked Services
Institution
21
University of Groningen / Centre for Information Technology - University of Groningen research database
Institution
17
Europe PMC
Domain
15
arXiv
Preprint
12
Le Centre pour la Communication Scientifique Directe - HAL - Diderot
Institution
11
Unknown Repository
Other Internet
10
Universitat Autònoma de Barcelona - Dipòsit Digital de Documents de la UAB
Institution
6
KU Leuven - Lirias
Institution
6
1 / 7

Data updated 18 August 2025

Share

Share

Share